OverviewSuggest Edit

BridgeBio is a a clinical-stage bioteccompany focused on discovering and developing drugs for patients with grievous genetic diseases. BridgeBio has built a portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage.

TypePublic
Founded2014
HQPalo Alto, CA, US
Websitebridgebio.com

Latest Updates

Employees (est.) (Dec 2019)248(+64%)
Revenue (FY, 2020)$8.2 M(-79%)
Share Price (Mar 2021)$62.2
Cybersecurity ratingBMore

Key People/Management at BridgeBio

Neil Kumar

Neil Kumar

Chief Executive Officer, Director
Charles Homcy

Charles Homcy

Chairman of Pharmaceuticals, Lead Director
Uma Sinha

Uma Sinha

Chief Scientific Officer
Brian C. Stephenson

Brian C. Stephenson

Chief Financial Officer
Richard Scheller

Richard Scheller

Chairman of Research & Development, Director
Eric Aguiar

Eric Aguiar

Director
Show more

BridgeBio Office Locations

BridgeBio has an office in Palo Alto
Palo Alto, CA, US (HQ)
421 Kipling St
Show all (1)

BridgeBio Financials and Metrics

BridgeBio Revenue

BridgeBio's revenue was reported to be $8.25 m in FY, 2020
USD

Revenue (FY, 2020)

8.2m

Net income (FY, 2020)

(505.5m)

EBIT (FY, 2020)

(474.5m)

Market capitalization (5-Mar-2021)

9.3b

Closing stock price (5-Mar-2021)

62.2

Cash (31-Dec-2020)

356.1m

EV

9.0b
BridgeBio's current market capitalization is $9.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

40.6m8.2m

General and administrative expense

13.3m43.6m94.4m145.7m

R&D expense

30.6m140.1m209.9m337.0m

Operating expense total

43.9m183.7m304.3m482.7m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

26.7m8.1m

General and administrative expense

23.5m34.3m38.0m36.0m

R&D expense

55.3m68.2m86.6m92.1m

Operating expense total

78.8m102.5m124.6m128.1m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

92.0m436.1m363.8m356.1m

Prepaid Expenses

5.1m9.1m22.6m35.7m

Current Assets

97.1m445.2m568.6m642.8m

PP&E

440.0k1.6m5.6m20.3m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

112.4m414.0m757.0m540.9m367.0m

Prepaid Expenses

22.1m19.8m21.0m26.7m

Current Assets

558.2m925.0m861.9m745.4m

PP&E

3.0m15.8m15.6m16.2m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(43.8m)(169.5m)(288.6m)(505.5m)

Depreciation and Amortization

260.0k245.0k

Accounts Payable

1.6m16.7m(4.7m)(735.0k)

Cash From Operating Activities

(40.5m)(136.6m)(253.6m)(399.7m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(204.4m)(104.1m)(240.3m)(370.5m)

Depreciation and Amortization

618.0k

Accounts Payable

(3.2m)4.2m4.0m547.0k

Cash From Operating Activities

(177.4m)(83.9m)(171.8m)(303.5m)
USDFY, 2017

Financial Leverage

-1.7 x
Show all financial metrics

BridgeBio Acquisitions / Subsidiaries

Company NameDateDeal Size
Adrenas Therapeutics, Inc.
Aspa Therapeutics, Inc.
BridgeBio Services, Inc.
Calcilytix Therapeutics, Inc.
CoA Therapeutics, Inc.
Dermecular Therapeutics, Inc.
Eidos Therapeutics, Inc.
Ferro Therapeutics, Inc.
Fortify Therapeutics, Inc.
Molecular Skin Therapeutics, Inc.
Show more

BridgeBio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

BridgeBio Online and Social Media Presence

Embed Graph

BridgeBio News and Updates

BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years

BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with …

BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting

Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET

BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate ML Bio Solu…

BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock

PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The selling stockholder…

BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations

PALO ALTO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular anomalies, today announced that the first patient has been dosed in its Phase 1/2 clinical trial o…
Show more

BridgeBio Blogs

Sr. Manager/Associate Director, Drug Substance Development

The post Sr. Manager/Associate Director, Drug Substance Development appeared first on BridgeBio.

Sr. Manager/Associate Director, Analytical Development

The post Sr. Manager/Associate Director, Analytical Development appeared first on BridgeBio.

Director, Formulation Development

The post Director, Formulation Development appeared first on BridgeBio.

Business Operations Manager

The post Business Operations Manager appeared first on BridgeBio.

Director/Senior Director, CMC Project Management

The post Director/Senior Director, CMC Project Management appeared first on BridgeBio.

Preclinical Associate Scientist

The post Preclinical Associate Scientist appeared first on BridgeBio.
Show more

BridgeBio Frequently Asked Questions

  • When was BridgeBio founded?

    BridgeBio was founded in 2014.

  • Who are BridgeBio key executives?

    BridgeBio's key executives are Neil Kumar, Charles Homcy and Uma Sinha.

  • How many employees does BridgeBio have?

    BridgeBio has 248 employees.

  • What is BridgeBio revenue?

    Latest BridgeBio annual revenue is $8.2 m.

  • What is BridgeBio revenue per employee?

    Latest BridgeBio revenue per employee is $33.3 k.

  • Who are BridgeBio competitors?

    Competitors of BridgeBio include WuXi AppTec, Hutchison China Meditech and Novartis.

  • Where is BridgeBio headquarters?

    BridgeBio headquarters is located at 421 Kipling St, Palo Alto.

  • Where are BridgeBio offices?

    BridgeBio has an office in Palo Alto.

  • How many offices does BridgeBio have?

    BridgeBio has 1 office.